Cargando…
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
BACKGROUND: Cardiovascular disease (CVD) is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), for whom the absolute risk of cardiovascular events is similar to people who have existing coronary artery disease. This is an update of a review published in 200...
Autores principales: | Palmer, Suetonia C., Navaneethan, Sankar D., Craig, Jonathan C., Johnson, David W., Perkovic, Vlado, Hegbrant, Jorgen, Strippoli, Giovanni F. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Paulista de Medicina - APM
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496564/ https://www.ncbi.nlm.nih.gov/pubmed/26760127 http://dx.doi.org/10.1590/1516-3180.20151336T2 |
Ejemplares similares
-
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2014) -
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
por: Würtz, Peter, et al.
Publicado: (2016) -
Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
por: Bose, Sucharita, et al.
Publicado: (2023) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023) -
What do Cochrane systematic reviews say about diabetic retinopathy?: O que as revisões sistemáticas da Cochrane dizem sobre retinopatia diabética?
por: Mozetic, Vania, et al.
Publicado: (2017)